Development of the new cancer immunotherapy using fusion cell-vaccine of iPSDC and cancer stem cell

人们普遍认为，难以获得足够数量的功能性树突状细胞（dc）是基于dc的免疫治疗中的一个严重问题。我们使用了诱导多能干细胞（iPS）衍生的dc （iPSDCs）。在这项研究中，我们比较了iPSDCs与骨髓源性dc （bmdc）的能力。我们通过腺病毒将hgp100基因转导到dc中，用转基因dc免疫小鼠一次。观察CD8（+）细胞毒T淋巴细胞（ctl）的细胞毒活性及接种后的治疗效果。我们的研究结果表明，hgp100特异性ctl表现出与BMDCs一样高的细胞毒性。此外，用转基因ipsdc接种疫苗获得的治疗效果与用bmdc接种疫苗一样高。本研究通过实验阐明了ipsdc与BMDCs具有同等的能力。因此，这种疫苗接种策略可能对未来的癌症疫苗临床应用有用。

It is generally accepted that the difficulty in obtaining a sufficient number of functional dendritic cells (DCs) is a serious problem in DC-based immunotherapy. We used the induced pluripotent stem (iPS) cell-derived DCs (iPSDCs). In this study, we examined the capacity of iPSDCs compared with that of bone marrow-derived DCs (BMDCs). We adenovirally transduced the hgp100 gene into DCs and immunized mice once with the genetically modified DCs. The cytotoxic activity of CD8 (+) cytotoxic T lymphocytes (CTLs) and the therapeutic efficacy of the vaccination were assayed. Our results showed that hgp100-specific CTLs exhibited as high a level of cytotoxicity as BMDCs. Moreover, vaccination with the genetically modified iPSDCs achieved as high a level of therapeutic efficacy as vaccination with BMDCs. This study clarified experimentally that iPSDCs have an equal capacity to BMDCs. This vaccination strategy may therefore be useful for future clinical application as a cancer vaccine.